Humacyte (NASDAQ:HUMA) Price Target Raised to $17.00 at Benchmark

Humacyte (NASDAQ:HUMA) had its target price raised by stock analysts at Benchmark from $15.00 to $17.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Benchmark’s target price would indicate a potential upside of 267.17% from the company’s current price.

Other equities analysts also recently issued research reports about the company. TD Cowen reissued a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price target on shares of Humacyte in a research note on Friday, September 20th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective (up from $12.00) on shares of Humacyte in a research report on Friday. Finally, BTIG Research restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Humacyte has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Down 0.2 %

Shares of HUMA stock opened at $4.63 on Monday. The company’s fifty day simple moving average is $4.83 and its two-hundred day simple moving average is $5.83. Humacyte has a 52 week low of $2.48 and a 52 week high of $9.97. The stock has a market cap of $582.73 million, a P/E ratio of -3.46 and a beta of 1.38. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

Insider Transactions at Humacyte

In related news, CEO Laura E. Niklason sold 811,172 shares of Humacyte stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the sale, the chief executive officer now directly owns 2,419,712 shares in the company, valued at $10,743,521.28. This trade represents a 25.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. The trade was a 17.67 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,500,000 shares of company stock valued at $6,606,799. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of HUMA. Renaissance Technologies LLC boosted its holdings in Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after buying an additional 524,600 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Humacyte in the third quarter worth about $596,000. Thrivent Financial for Lutherans purchased a new stake in shares of Humacyte during the 3rd quarter worth about $712,000. State Street Corp grew its position in shares of Humacyte by 66.1% during the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after acquiring an additional 1,895,529 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.